Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6atezolizumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Drug Combinations × Breast × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡